查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197819

眼科手术辅助器具市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Ophthalmic Viscosurgical Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，眼科手术辅助市场预计将以 6.5% 的复合年增长率增长。

最初，随着全球 COVID-19 病例的增加，世界各国政府实施了封锁措施以阻止 SARS-CoV-2 病毒的传播，开设了眼科诊所和医院。不仅医院就诊人数下降，但是许多程序被取消或推迟，不仅影响了患者，也影响了研究市场。 例如，根据 Parul C Gupta 及其同事于 2021 年在印度眼科学杂誌上发表的一项研究，接受调查的诊所预计将进行 7,500 例白内障手术。 然而，由于大流行，只能提供 2,500 台手术。 数据表明，在 COVID-19 大流行期间，白内障手术显着减少。 Gabriel Ayubet.al 发表的一项研究表明，总数分别减少了 92.52%、93.84%、72.74% 和 19.63%。 数据显示，COVID-19对眼科疾病的诊断和治疗产生了负面影响，对市场产生了负面影响。 此外，自解除限制和供应链正常化以来，市场已经强劲復苏。 门诊人数的增加和对眼科手术的所有限制的取消正在推动预测期内的市场復苏。

这是由于人口迅速老龄化、糖尿病患病率增加以及白内障和青光眼手术数量增加所致。 随着世界老龄化人口的增加，人们更容易患上眼疾。 例如，根据世界卫生组织（WHO）2021年10月发布的数据，人口老龄化的速度比过去快得多，到2030年，全球六分之一的人将超过10岁。据报导，60岁以上 预计 60 岁及以上人口的比例将从 2020 年的 10 亿增加到 2030 年的 14 亿。 因此，预计人口老龄化加剧将在预测期内推动市场增长。

糖尿病会损害您的眼睛并导致视力下降或失明。 糖尿病患者可能会遇到各种称为糖尿病眼病的眼部问题。 这些疾病包括青光眼、白内障、糖尿病性黄斑、糖尿病性视网膜病变等。因此，糖尿病患病率的增加预计将导致眼部疾病，从而促进市场增长。 例如，根据 IDF 糖尿病地图集第十版 2021，糖尿病将在 2021 年影响全球约 5.37 亿人（20-79 岁）。 预计到 2030 年糖尿病将影响 6.43 亿人，到 2045 年将影响 7.83 亿人。 因此，糖尿病是眼病最常见的原因，糖尿病患病率的增加预计将在预测期内提振市场。

但是，替代疗法的可用性可能会阻碍市场增长。

眼科手术辅助设备的市场趋势

白内障手术领域有望健康成长

预计将推动白内障手术领域发展的关键因素是白内障患病率上升和全球老年人口不断增加。 例如，根据 2021 年 1 月发表在 Sage Journal 上的一项研究，2020 年东非每百万居民中有 3,000 至 10,000 例新病例。 埃塞俄比亚有超过 500,000 例失明病例和 120 万例严重视力损伤病例，白内障是可预防性失明和视力损伤的主要原因。 白内障是所有年龄段视力丧失的第二大原因，占全球失明病例的 50% 和低视力病例的 33%，导致全球白内障和白内障相关疾病的增加。可以看出， 因此，对白内障手术设备的需求不断增加，推动了该行业的增长。

此外，白内障手术的增加预计将在预测期内推动内臟手术设备市场的需求。 根据经济合作与发展组织 (OECD) 的数据，到 2022 年，爱尔兰的白内障手术人数将增加到 25,942 人，以色列的白内障手术人数到 2020 年将增加到 71,920 人。 此外，2020 年韩国的白内障手术数量增加到 702,621 例。 因此，预计白内障手术的增加将推动对粘弹性手术器械市场的需求，从而促进细分市场的增长。

此外，主要市场参与者推出的产品将在整个预测期内进一步扩大市场。 例如，博士伦在 2021 年 4 月报告称，美国食品和药物管理局 (FDA) 批准了 ClearVisc 分散眼科手术辅助剂 (OVD) 用于眼科手术。

因此，上述所有因素都有望在预测期内推动市场增长。

预计在预测期内北美将占据很大的市场份额

由于人口老龄化、眼科医疗设施的普及、医疗支出的增加以及医疗基础设施的完善，预计北美将占据全球眼科手术救助市场的很大份额。. 根据美国疾病控制和预防中心 2021 年的数据，到 2020 年，美国将有大约 3010 万人患有白内障。 此外，美国疾病控制与预防中心 2020 年发布的数据显示，到 2050 年，由于美国糖尿病和其他慢性病患病率上升，约有 896 万美国人将出现无法矫正的视力丧失。 因此，预计眼病患病率的增加将在预测期内推动市场增长。

此外，眼科疾病高发的老龄化人口有望推动市场扩张。 根据加拿大统计局的数据，到 2022 年 4 月，700 万加拿大人（占人口的 19.0%）将在 2021 年达到或超过 65 岁。 与 0-14 岁的儿童相比，65 岁及以上的人口每六年翻一番。 因此，预计老年人口的增加将在预测期内推动市场增长。

此外，市场参与者采用的各种有机和无机策略可能会支持市场的增长。 例如，2022 年 8 月，Glaukos Corporation 就 iStent infinite 获得了美国食品和药物管理局 (FDA) 的 510(k) 许可。 这是一种海绵体微旁路术，用作降低原发性开角型青光眼患者升高的眼内压 (IOP) 的唯一手术，该患者先前的药物和手术治疗无法控制。

因此，上述所有因素都有望在预测期内推动市场增长。

眼科手术辅助用品市场竞争者分析

眼科手术辅助设备市场竞争适中，由几家大型企业组成。 目前主导市场的公司包括强生公司、Carl Zeiss Meditec AG、Bausch & Lomb Incorporated、Rayner Intraocular Lenses Limited、Alcon AG、Beaver-Visitec International Inc、Bohus Biotech AB、Truviz Ophthalmic、Amring Pharmaceutical Inc.。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 老年人口迅速增加
    • 糖尿病患病率增加
    • 白内障和青光眼手术的数量增加
  • 市场製约因素
    • 替代疗法的可用性
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按类型
    • 凝聚力
    • 去中心化
    • 黏合剂
  • 按供应来源
    • 生物
    • 动物起源
    • 半合成
  • 通过使用
    • 青光眼手术
    • 白内障手术
    • 角膜移植
    • 其他用途
  • 区域信息
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Johnson & Johnson
    • Carl Zeiss Meditec AG
    • Bausch & Lomb Incorporated
    • Rayner Intraocular Lenses Limited
    • Alcon AG
    • Beaver-Visitec International Inc.
    • Bohus Biotech AB
    • Truviz Ophthalmic
    • Amring Pharmaceutical Inc.
    • Advin Health Care
    • Ophtechnics Unlimited
    • EC21 Inc.

第7章 市场机会与今后动向

简介目录
Product Code: 69159

The ophthalmic viscosurgical devices market is expected to register a CAGR of 6.5% during the forecast period.

Initially, with the increasing COVID-19 cases around the world, governments around the globe implemented lockdown measures to stop the spread of the SARS-CoV-2 virus, which not only led to a drop in footfall in clinics and hospitals for eye care but also led to the cancellation or postponement of many procedures which had its impact on the patients as well as the studied market. For instance, according to a research study published by Parul C Gupta et al. in 2021 in the Indian Journal of Ophthalmology, the studied clinic was expected to perform 7,500 cataract procedures. Still, due to the pandemic, they could serve only 2,500 procedures. This data suggested a significant decrease in cataract procedures during the COVID-19 pandemic. As per the research study published by Gabriel Ayubet. al., in November 2021, on the comparison of the pre-pandemic and pandemic periods data for glaucoma patients in a tertiary center, it was observed the total number of outpatient clinical visits, visual field exams, surgical procedures, and medications released decreased by 92.52%, 93.84%, 72.74%, and 19.63%, respectively. This data shows a negative impact of COVID-19 on diagnosing and treating ocular disorders; thus, the market suffered negatively. Moreover, the market has been making a strong comeback since the limitations were lifted and normalized the supply chain. Increased outpatient visits and the removal of all restrictions on ophthalmic procedures have been driving the market recovery over the projected period.

This is attributed to the rapidly increasing geriatric population, increasing prevalence of diabetes, and an increasing number of cataract and glaucoma surgeries performed. The rising geriatric population worldwide is more prone to ocular disorders. For instance, the data published in October 2021 by the World Health Organization (WHO) reported that the pace of population aging is much faster than in the past, and by 2030, 1 in 6 people in the world will be aged 60 years or over. The share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion by 2030. Thus, an increase in the geriatric population is expected to boost market growth over the forecast period.

Diabetes can damage the eyes, resulting in vision problems or even blindness. People with diabetes may experience various eye issues known as diabetic eye disease. These ailments include glaucoma, cataracts, diabetic macular, and diabetic retinopathy, and thus growing prevalence of diabetes is expected to cause eye diseases, thereby boosting the market growth. For instance, according to the IDF Diabetes Atlas Tenth Edition 2021, diabetes has affected around 537 million persons (20-79 years) in 2021 across the world. Diabetes is expected to affect 643 million people by 2030 and 783 million by 2045. Thus, the increasing prevalence of diabetes, the most common cause of ophthalmic disease, is expected to boost the market over the forecast period.

However, the availability of alternative procedures may hamper the market growth.

Ophthalmic Viscosurgical Devices Market Trends

Cataract Surgery Segment is Estimated to Witness Healthy Growth

The significant factors expected to drive growth in the cataract surgery segment are the increasing prevalence of cataracts and the growing geriatric population globally. For instance, according to the research study published in Sage Journal in January 2021, there were between 3,000 and 10,000 new cases per million inhabitants in East Africa in 2020. With more than 0. 5 million cases of blindness and 1. 2 million cases of severe visual impairment, cataract was the primary reason for preventable blindness and impaired vision in Ethiopia. A cataract is the second-leading cause of impaired vision in persons of all ages, accounting for 50% of all cases of blindness and 33% of all cases of low vision globally, which shows an increase in cataract and cataract-related illnesses globally. Thus, the demand for cataract surgery devices for treatment is increasing, fueling growth in the segments.

Moreover, a growing number of cataract surgeries is expected to drive the demand for the viscosurgical devices market over the forecast period. According to the Organization for Economic Co-operation and Development (OECD), in 2022, cataract surgeries in Ireland climbed to 25,942 in 2020, and cataract procedures in Israel increased to 71,920 in 2020. Furthermore, the number of cataract procedures conducted in Korea increased to 702,621 in 2020. Thus, rising cataract surgeries are expected to drive the demand in the viscosurgical devices market, thereby boosting segment growth.

Furthermore, product launch by the key market players further expands the market throughout the forecast period. For instance, in April 2021, Bausch + Lomb reported that the United States Food and Drug Administration (FDA) approved ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery.

Thus, all the above factors are expected to boost market growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market during the Forecast Period

North America is expected to hold a significant market share in the global ophthalmic viscosurgical devices market due to the increasing aging population, improved access to ophthalmic care facilities, increasing healthcare expenditure, and well-established healthcare infrastructure. According to the Centers for Disease Control and Prevention 2021, about 30.1 million people were affected by cataracts in the United States in 2020. Additionally, per data published by the Centers for Disease Control and Prevention in 2020, around 8.96 million Americans will suffer from uncorrectable vision impairment by 2050 due to the increasing epidemics of diabetes and other chronic diseases in the United States. Thus, increasing the prevalence of ophthalmic diseases is expected to boost market growth over the forecast period.

Additionally, a senior population that is more prone the ophthalmic diseases is expected to support the market expansion. According to Statistics Canada, in April 2022, 7 million people, or 19.0% of the population, in Canada were 65 years or older in 2021. The number of seniors 65 and over doubles every six years compared to children ages 0 to 14. Thus, rising in the geriatric population is expected to boost the market growth over the forecast period.

Moreover, various organic and inorganic strategies adopted by the market players are likely to support the market's growth. For instance, in August 2022, Glaukos Corporation received 510(k) clearance from the United States Food and Drug Administration (FDA) for the iStent infinite. It is a trabecular micro-bypass system indicated for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma uncontrolled by prior medical and surgical therapy.

Thus, all the above factors are expected to boost market growth over the forecast period.

Ophthalmic Viscosurgical Devices Market Competitor Analysis

The ophthalmic viscosurgical devices market is moderately competitive and consists of several major players. Some of the companies currently dominating the market include Johnson & Johnson, Carl Zeiss Meditec AG, Bausch & Lomb Incorporated, Rayner Intraocular Lenses Limited, Alcon AG, Beaver-Visitec International Inc., Bohus Biotech AB, Truviz Ophthalmic, and Amring Pharmaceutical Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rapidly Increasing Geriatric Population
    • 4.2.2 Increasing Prevalence of Diabetes
    • 4.2.3 Increasing Number of Cataract and Glaucoma Surgeries Performed
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatment Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Type
    • 5.1.1 Cohesive
    • 5.1.2 Dispersive
    • 5.1.3 Viscoadaptive
  • 5.2 By Source
    • 5.2.1 Biological
    • 5.2.2 Animal
    • 5.2.3 Semi-synthetic
  • 5.3 By Application
    • 5.3.1 Glaucoma Surgery
    • 5.3.2 Cataract Surgery
    • 5.3.3 Corneal Grafting
    • 5.3.4 Other Applications
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Johnson & Johnson
    • 6.1.2 Carl Zeiss Meditec AG
    • 6.1.3 Bausch & Lomb Incorporated
    • 6.1.4 Rayner Intraocular Lenses Limited
    • 6.1.5 Alcon AG
    • 6.1.6 Beaver-Visitec International Inc.
    • 6.1.7 Bohus Biotech AB
    • 6.1.8 Truviz Ophthalmic
    • 6.1.9 Amring Pharmaceutical Inc.
    • 6.1.10 Advin Health Care
    • 6.1.11 Ophtechnics Unlimited
    • 6.1.12 EC21 Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS